Preclinical News and Research

RSS

Lorus identifies novel class of lead drug candidates from small molecule anticancer program

Lorus Therapeutics has announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from the Company's small molecule program.

24 Aug 2005

Disease modifying activity of 2ME2 demonstrated in preclinical rheumatoid arthritis studies

EntreMed a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, has announced the presentation of positive preclinical results for its lead compound, 2-methoxyestradiol (2ME2), in models of rheumatoid arthritis.

24 Aug 2005

Non-invasive imaging may help predict type 1 diabetes and response to treatment in humans

A key obstacle to early detection of type 1 diabetes - as well as to rapid assessment of the effectiveness of therapeutic intervention - has been the lack of direct, non-invasive technologies to visualize inflammation in the pancreas, an early manifestation of disease.

22 Aug 2005

Combined gene therapy eliminates glioblastoma multiforme in lab studies

Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.

15 Aug 2005

Australian scientists rejuvenate the immune systems of mice and humans using a common hormone

The scientists, led by Associate Professor Richard Boyd and Dr Jayne Sutherland from the Monash Immunology and Stem Cell Laboratories, have revitalised the thymus which produces the T cells required to fight infection but which shuts down from early adulthood.

11 Aug 2005

Early warning aigns of Alzheimer's show up across cognitive areas years before official diagnosis

By combing through dozens of Alzheimer's disease (AD) studies, psychologists have gained a clear picture of cognitive problems in people who will develop the degenerative brain disease.

4 Aug 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

Living Cell Technologies announces results for treating Huntington's disease

Living Cell Technologies announced pre-clinical results today showing its brain protection product, NeurotrophinCell (NtCell) produces a marked reduction in the size of brain lesions in a Huntington's disease (HD) model.

2 Aug 2005

People have signs of Alzheimer's years before diagnosis

Psychologists say that after examining dozens of Alzheimer's studies, they now have a clear picture of the cognitive problems which will develop in people with the degenerative brain disease.

1 Aug 2005

New recommendations can help medical arms of the military meet their mission

As reported last December in the New England Journal of Medicine, the U.S. military's on-the-ground surgical strategy now aims at "damage control, not definitive repair, unless it can be done quickly."

1 Aug 2005

People can show early warning signs of Alzheimer's disease years before they are officially diagnosed

By combing through dozens of Alzheimer's disease (AD) studies, psychologists have gained a clear picture of cognitive problems in people who will develop the degenerative brain disease.

1 Aug 2005

Participants in the gene therapy market discover new ways to improve clinical efficiency and generate revenue

The gene therapy market has had limited success with products during the clinical development process. Due to toxicological complications and poor therapy efficacy, healthcare authorities have suspended several gene therapy trials worldwide.

28 Jul 2005

Potential new treatment for nerve damage caused by diabetes

Research into a new treatment for nerve damage caused by diabetes could bring relief to millions of diabetic patients, say experts.

From The University of Manchester 26 Jul 2005

Direct relationship between inflammation and glucose levels

Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.

26 Jul 2005

Provectus to begin clinical trials of new cancer treatment, PV-10

Provectus Pharmaceuticals announced today that it has obtained final clearance to begin the first Phase 1 clinical trial of PV-10, the Company's lead cancer treatment.

21 Jul 2005

Role of IL-24 in regulating the immune system

Researchers at Introgen Therapeutics and their collaborators at The University of Texas M. D. Anderson Cancer Center have published new findings on the role of IL-24 in regulating the immune system in the current online issue of the Journal of Leukocyte Biology.

21 Jul 2005

New design for HIV vaccine trials in animals

Emory University researchers have proposed a new design for HIV vaccine trials in animals that would more closely mimic how humans are exposed to the virus - potentially giving AIDS researchers a more effective tool in developing successful treatments to prevent HIV infection.

20 Jul 2005

Potential use of NH neurotransmitters as novel source for psychiatric drugs

Physiologists and medical researchers have long recognized the important endocrine roles played by the pituitary hormones oxytocin (OT) and vasopressin (VP) on peripheral systems in lactation, uterine contraction and urine concentration.

19 Jul 2005

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Human Genome Sciences has announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin

19 Jul 2005

Tool to predict potential ovarian failure after radiation

Doctors in the United Kingdom have created a table to predict when a woman who has undergone radiation therapy as a part of cancer treatment regimen in her abdominal or pelvic area may become sterile

6 Jul 2005

Preclinical News and Research

Lorus identifies novel class of lead drug candidates from small molecule anticancer program

Disease modifying activity of 2ME2 demonstrated in preclinical rheumatoid arthritis studies

Non-invasive imaging may help predict type 1 diabetes and response to treatment in humans

Combined gene therapy eliminates glioblastoma multiforme in lab studies

Australian scientists rejuvenate the immune systems of mice and humans using a common hormone

Early warning aigns of Alzheimer's show up across cognitive areas years before official diagnosis

Genelabs drug discovery team advances compounds against the hepatitis C virus

Living Cell Technologies announces results for treating Huntington's disease

People have signs of Alzheimer's years before diagnosis

New recommendations can help medical arms of the military meet their mission

People can show early warning signs of Alzheimer's disease years before they are officially diagnosed

Participants in the gene therapy market discover new ways to improve clinical efficiency and generate revenue

Potential new treatment for nerve damage caused by diabetes

Direct relationship between inflammation and glucose levels

Provectus to begin clinical trials of new cancer treatment, PV-10

Role of IL-24 in regulating the immune system

New design for HIV vaccine trials in animals

Potential use of NH neurotransmitters as novel source for psychiatric drugs

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Tool to predict potential ovarian failure after radiation

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics